Clinical trials: Dependence Addictive
Alcohol Dependence
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
This was a study of the effects of VIVITROL® on alcohol cue-induced craving and the associated brain activation patterns in alcohol-dependent adults who had recently completed alcohol detoxification and were seeking further…
- Trial name
- NCT00511836
- Testing
- VIVITROL 380 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Alkermes, Inc.
Opioid Use Disorder
A Stepped-Wedge Cluster Randomized Trial of a Digital App to Support Medication-Assisted Treatment in Individuals With Opioid Use Disorder
The goal of this clinical trial is to learn if a mobile health app called Recovery Connect can help people stay in treatment for opioid use disorder.
- Trial name
- SMART-OUD (NCT07140926)
- Testing
- Recovery Connect
- Where
- 9 sites in United States
- Volunteers
- 1,524 people
- Sponsor
- Bright Therapeutics
Opioid-Related Disorders, Opiate Addiction
A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
To evaluate the reasons patients go to more than one prescriber or more than one pharmacy to obtain prescriptions opioids and assess whether the percentage of patients reporting misuse, abuse and/or diversion increases across…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02667158
- Testing
- Survey to Eval Relation between Shopping and Misuse, Abuse
- Volunteers
- 1,085 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Opioid-Related Disorders, Opiate Addiction
A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire
The purpose of this study is to evaluate the patient usability and reliability of the POMAQ survey to evaluate opioid misuse and abuse among adults with chronic moderate to severe pain, including patients who are opioid abusers…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- POMAQ (NCT02660606)
- Testing
- Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Cocaine Addiction, Cocaine Dependence
Vigabatrin for the Treatment of Cocaine Dependency
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's…
- Trial name
- NCT01281202
- Testing
- Vigabatrin
- Where
- 13 sites in United States
- Volunteers
- 207 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Drug Addiction
Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)
This study was a survey of drug users who obtain buprenorphine from the black market and have used buprenorphine during the last month.
- Trial name
- NCT00756353
- Volunteers
- 600 people
- Sponsor
- Indivior Inc.
Substance Dependence
Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement
This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese.
- Trial name
- NCT01039454
- Testing
- GSK598809 Capsules
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Use Disorder, Opioid Withdrawal
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
IBO-CARE is a single-site Phase 1/2a study evaluating the safety, tolerability, feasibility and preliminary outcomes of medically supervised ibogaine with 12 months of recovery support in adults with moderate-to-severe opioid use…
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
- Trial name
- IBO-CARE (NCT07871877)
- Testing
- Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Clive Michelsen
Nicotine Addiction, Drug Addiction
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
This study is evaluating the efficacy of Treatment A for short-term smoking cessation through a blinded randomized controlled trial (RCT) vs.Treatment B.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT05440721
- Testing
- Treatment A with device Clickotine® (Active intervention), Treatment B with smoking education (control)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Click Therapeutics, Inc.
Opioid-Related Disorders, Opiate Addiction
Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication
The purpose is to validate the PRISM-5-Op as a measurement of prescription opioid substance use disorder.
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02660619
- Testing
- Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)
- Volunteers
- 606 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Substance Use Disorders, Addiction, Alcohol
Evaluating the Effectiveness of Mobile Self-guided Psychological Interventions to Reduce Relapse in Substance Use Disorder
The aim of the study is to evaluate the effectiveness of mobile interventions in reducing craving and lapses in patients diagnosed with Substance Use Disorder.
- Conditions
- Substance Use Disorders, Addiction, Alcohol, Addiction, Substance
- Trial name
- NCT05730504
- Testing
- Mobile app-based self-guided interventions
- Where
- Poland
- Volunteers
- 400 people
- Sponsor
- PredictWatch
Cocaine Use Disorder, Cocaine Dependence
TDCS for Cocaine Addiction Craving
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT03833583
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Opioid-Related Disorders, Opiate Addiction
A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Opioids for the Treatment of Chronic Pain
The purpose of this study is to quantify the serious risks of prescription opioid misuse or abuse or opioid use disorder (OUD) associated with the long term use of opioid analgesics for management of chronic pain, among patients…
- Conditions
- Opioid-Related Disorders, Opiate Addiction, Narcotic Abuse, Drug Abuse
- Trial name
- NCT02751762
- Testing
- Observation Only
- Where
- 2 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Member Companies of the Opioid PMR Consortium
Opioid Abuse and Addiction
Nalmefene Implant in Healthy Subjects
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks.
- Trial name
- NCT07325279
- Testing
- 1 Nalmefene implant, 2 Nalmefene implants
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ReacX Pharmaceuticals, Inc.
Drug Abuse
Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse
The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse.
- Trial name
- NCT00671632
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Takeda